Schlieren – The journal “Nature Communications” publishes preclinical data on an experimental therapy with the human antibody NI203. This is being further developed by Neurimmune for the treatment of type 2 diabetes.
The biotech company Neurimmune in Schlieren reports the publication of an article on preclinical data on its human antibody NI203 for the treatment of diabetes in the internationally renowned journal "Nature Communications". The article "A human antibody against pathological IAPP aggregates protects beta cells in type 2 diabetes models" in the current issue describes a monoclonal antibody that targets pathological aggregates of the beta cell peptide hormone islet amyloid polypeptide (IAPP) to help treat type 2 diabetes.
«We are pleased with these results, which provide the scientific basis for the development of NI203 as a potential disease-modifying treatment for patients with type 2 diabetes and progressive beta cell loss,» Jan Grimm, CSO of Neurimmune, is quoted as saying. «Knocking down pathological pancreatic IAPP oligomers is a novel therapeutic strategy that is expected to lead to durable control of beta cell health.»
Type 2 diabetes, according to the media release, is a chronic metabolic disease characterized by insulin resistance and progressive dysfunction and loss of insulin-producing pancreatic beta cells, leading to insulin deficiency and elevated blood glucose. The main cause of beta cell failure in type 2 diabetes is not known, but the accumulation of IAPP aggregates in pancreatic islets is a key contributor to the decline in beta cell function and cell mass, according to the Neuroimmune report.
Neurimmune was spun off from the University of Zurich(UZH) in 2006 and is located in the Bio-Technopark Schlieren-Zurich. ce/gba
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More Information